Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs
Breast cancer is the most common malignant tumors in females. Although the conventional treatment has demonstrated a certain effect, some limitations still exist. The Rho guanosine triphosphatase (GTPase) Cdc42 (Cell division control protein 42 homolog) is often upregulated by some cell surface rece...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/8/2/146 |
id |
doaj-8e3f7af0cb9447bb903b4ff22541f2dc |
---|---|
record_format |
Article |
spelling |
doaj-8e3f7af0cb9447bb903b4ff22541f2dc2020-11-24T22:09:56ZengMDPI AGCells2073-44092019-02-018214610.3390/cells8020146cells8020146Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAsYu Zhang0Jun Li1Xing-Ning Lai2Xue-Qiao Jiao3Jun-Ping Xiong4Li-Xia Xiong5Department of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaBreast cancer is the most common malignant tumors in females. Although the conventional treatment has demonstrated a certain effect, some limitations still exist. The Rho guanosine triphosphatase (GTPase) Cdc42 (Cell division control protein 42 homolog) is often upregulated by some cell surface receptors and oncogenes in breast cancer. Cdc42 switches from inactive guanosine diphosphate (GDP)-bound to active GTP-bound though guanine-nucleotide-exchange factors (GEFs), results in activation of signaling cascades that regulate various cellular processes such as cytoskeletal changes, proliferation and polarity establishment. Targeting Cdc42 also provides a strategy for precise breast cancer therapy. In addition, Cdc42 is a potential target for several types of non-coding RNAs including microRNAs and lncRNAs. These non-coding RNAs is extensively involved in Cdc42-induced tumor processes, while many of them are aberrantly expressed. Here, we focus on the role of Cdc42 in cell morphogenesis, proliferation, motility, angiogenesis and survival, introduce the Cdc42-targeted non-coding RNAs, as well as present current development of effective Cdc42-targeted inhibitors in breast cancer.https://www.mdpi.com/2073-4409/8/2/146breast cancerCdc42cytoskeleton remodelingtumor progressiontargeted therapynon-coding RNAs |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yu Zhang Jun Li Xing-Ning Lai Xue-Qiao Jiao Jun-Ping Xiong Li-Xia Xiong |
spellingShingle |
Yu Zhang Jun Li Xing-Ning Lai Xue-Qiao Jiao Jun-Ping Xiong Li-Xia Xiong Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs Cells breast cancer Cdc42 cytoskeleton remodeling tumor progression targeted therapy non-coding RNAs |
author_facet |
Yu Zhang Jun Li Xing-Ning Lai Xue-Qiao Jiao Jun-Ping Xiong Li-Xia Xiong |
author_sort |
Yu Zhang |
title |
Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs |
title_short |
Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs |
title_full |
Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs |
title_fullStr |
Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs |
title_full_unstemmed |
Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs |
title_sort |
focus on cdc42 in breast cancer: new insights, target therapy development and non-coding rnas |
publisher |
MDPI AG |
series |
Cells |
issn |
2073-4409 |
publishDate |
2019-02-01 |
description |
Breast cancer is the most common malignant tumors in females. Although the conventional treatment has demonstrated a certain effect, some limitations still exist. The Rho guanosine triphosphatase (GTPase) Cdc42 (Cell division control protein 42 homolog) is often upregulated by some cell surface receptors and oncogenes in breast cancer. Cdc42 switches from inactive guanosine diphosphate (GDP)-bound to active GTP-bound though guanine-nucleotide-exchange factors (GEFs), results in activation of signaling cascades that regulate various cellular processes such as cytoskeletal changes, proliferation and polarity establishment. Targeting Cdc42 also provides a strategy for precise breast cancer therapy. In addition, Cdc42 is a potential target for several types of non-coding RNAs including microRNAs and lncRNAs. These non-coding RNAs is extensively involved in Cdc42-induced tumor processes, while many of them are aberrantly expressed. Here, we focus on the role of Cdc42 in cell morphogenesis, proliferation, motility, angiogenesis and survival, introduce the Cdc42-targeted non-coding RNAs, as well as present current development of effective Cdc42-targeted inhibitors in breast cancer. |
topic |
breast cancer Cdc42 cytoskeleton remodeling tumor progression targeted therapy non-coding RNAs |
url |
https://www.mdpi.com/2073-4409/8/2/146 |
work_keys_str_mv |
AT yuzhang focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas AT junli focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas AT xingninglai focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas AT xueqiaojiao focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas AT junpingxiong focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas AT lixiaxiong focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas |
_version_ |
1725809972888993792 |